Abcam, ab266927, Human TREX1 knockout A549 cell line

Size: 2 x 1000000Cells / vial / 1000000Cells / vial
TREX1 KO cell line available to order. KO validated by Western blot. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 1 and 4 bp insertion in exon 1. To order both knockout and wild-type control cells: select 2 x 1000000Cells/vial. To order only knockout cells: select 1000000Cells/vial.
Key facts
Cell type:A549,
Species or organism:Human,
Tissue:Lung,
Form:LiquidSee storage information,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 1 and 4 bp insertion in exon 1,
Disease:Carcinoma

Product details:
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-TREX1, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Shipped at conditions-Dry Ice, Appropriate short-term storage conditions--196°C, Appropriate long-term storage conditions--196°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
TREX1 also known as Three Prime Repair Exonuclease 1 acts as a DNA exonuclease which degrades single-stranded DNA from the 3' end. This protein exhibits a mass of 33 kDa. TREX1's expression is largely found in the cytoplasm of many cell types including those in the immune system and various tissues like the liver spleen and heart. Through its enzymatic activity TREX1 helps maintain genomic stability by processing DNA intermediates that arise from incomplete DNA replication or repair processes.
Biological function summary
TREX1 removes excessive DNA that might trigger immune responses. It is not a part of a large protein complex but works closely with substrates involved in DNA repair and replication. By degrading abnormal DNA TREX1 prevents the initiation of inappropriate immune responses that could result in autoimmunity. Its functionality is essential in preventing the cell from converting these DNA fragments into ligands for DNA sensors which could activate immune signaling pathways.
Pathways
TREX1 plays a significant role in the DNA damage response and innate immune pathways. In the DNA damage response pathway TREX1 functions alongside proteins like ATR and ATM which address DNA replication stress and repair. Within the innate immune pathway it interacts with cGAS (cyclic GMP-AMP synthase) which can become activated in response to cytosolic DNA leading to the production of type I interferons - powerful immune modulators.
Mutations in TREX1 have been linked to autoimmune diseases such as Aicardi-Goutières syndrome and systemic lupus erythematosus. In these conditions the altered or deficient TREX1 leads to the accumulation of DNA in the cytoplasm falsely triggering an antiviral immune response. This relationship with cGAS is critical as the cGAS-STING pathway becomes activated due to the presence of unprocessed DNA resulting in chronic inflammation and contributing to the autoimmune pathology observed in these disorders.